Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection
| Autor: | J. Vandepitte, L. Baert, I. Billiet |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Microbiology (medical) medicine.medical_specialty medicine.medical_treatment Urinary system Administration Oral Fosfomycin Placebo Postoperative Complications Double-Blind Method medicine Humans Prospective Studies Transurethral Prostatic Resection Prospective cohort study Transurethral resection of the prostate Prostatectomy business.industry General Medicine Surgery Catheter Infectious Diseases Nitrofurantoin Urinary Tract Infections business medicine.drug |
| Zdroj: | Infection. 18:S103-S106 |
| ISSN: | 1439-0973 0300-8126 |
| DOI: | 10.1007/bf01643437 |
| Popis: | A prospective randomized controlled double-blind study was performed on 61 patients undergoing transurethral resection of the prostate. The first group of 31 patients received 3 g fosfomycin trometamol p.o. each on the evening before and after the operation; the second group of 30 patients received a placebo. Urine samples were taken by catheter puncture 24 and 48 h postoperative. After removal of the catheter (day 5) the first midstream urine was collected for culture, and from that moment on all patients were treated with a nitrofurantoin derivative for two weeks. Although the same strict antiseptic measures were standard practice for both groups, the incidence of early postoperative urinary tract infections was significantly lower for the fosfomycin trometamol group (0/31 versus 6/30 in placebo recipients). None of the patients suffered from a major symptomatic or complicated infection. There were no side effects registered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink